hydroxychloroquine has been researched along with Nervous System Disorders in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of chloroquine (Aralen) phosphate and hydroxychloroquine (Plaquenil) sulfate in the treatment of patients with neurosarcoidosis who either do not respond to corticosteroid therapy or develop unacceptable side effects." | 7.70 | Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. ( Sharma, OP, 1998) |
| " Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple's disease, fungal infections), rheumatological (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren's syndrome), and other immunological diseases." | 4.98 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. ( Koudriavtseva, T; Plantone, D, 2018) |
| "To assess the efficacy of chloroquine (Aralen) phosphate and hydroxychloroquine (Plaquenil) sulfate in the treatment of patients with neurosarcoidosis who either do not respond to corticosteroid therapy or develop unacceptable side effects." | 3.70 | Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. ( Sharma, OP, 1998) |
| "Neurological complications of systemic lupus erythematosus (SLE) are wide and may rarely involve the peripheral nervous system." | 1.72 | Broadening the spectrum of the neurological complications in systemic lupus erythematosus: A patient with meningoradiculitis. ( Bardel, B; Gendre, T; Limal, N; Matthys, A; Megdiche, I; Planté-Bordeneuve, V; Remy, P, 2022) |
| "Primary aim was to assess prevalence and severity of potential and real drug-drug interactions (DDIs) among therapies for COVID-19 and concomitant medications in hospitalized patients with confirmed SARS-CoV-2 infection." | 1.62 | Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. ( Cantudo-Cuenca, MD; Contreras-Macías, E; Fernández-Fuertes, M; Gutiérrez-Pizarraya, A; Lao-Domínguez, FA; Macías, J; Morillo-Verdugo, R; Pineda, JA; Pinilla-Fernández, A; Rincón, P, 2021) |
| "Chloroquine is a neuromyotoxin that affects nerves and cardiac and skeletal muscles." | 1.27 | Chloroquine neuromyotoxicity. Clinical and pathologic perspective. ( Chou, SM; Estes, ML; Ewing-Wilson, D; Hanson, M; Mitsumoto, H; Ratliff, NB; Shirey, E, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Matthys, A | 1 |
| Megdiche, I | 1 |
| Bardel, B | 1 |
| Remy, P | 1 |
| Limal, N | 1 |
| Planté-Bordeneuve, V | 1 |
| Gendre, T | 1 |
| Fujieda, Y | 1 |
| Cantudo-Cuenca, MD | 1 |
| Gutiérrez-Pizarraya, A | 1 |
| Pinilla-Fernández, A | 1 |
| Contreras-Macías, E | 1 |
| Fernández-Fuertes, M | 1 |
| Lao-Domínguez, FA | 1 |
| Rincón, P | 1 |
| Pineda, JA | 1 |
| Macías, J | 1 |
| Morillo-Verdugo, R | 1 |
| Plantone, D | 1 |
| Koudriavtseva, T | 1 |
| Sharma, OP | 1 |
| Granel, B | 1 |
| Gaudy, C | 1 |
| Serratrice, J | 1 |
| de Roux-Serratrice, C | 1 |
| Félician, O | 1 |
| Swiader, L | 1 |
| Pache, X | 1 |
| Ceccaldi, M | 1 |
| Balzamo, M | 1 |
| Donnet, A | 1 |
| Manera, L | 1 |
| Raybaud, C | 1 |
| Disdier, P | 1 |
| Weiller, PJ | 1 |
| Estes, ML | 1 |
| Ewing-Wilson, D | 1 |
| Chou, SM | 1 |
| Mitsumoto, H | 1 |
| Hanson, M | 1 |
| Shirey, E | 1 |
| Ratliff, NB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Nervous System Disorders
| Article | Year |
|---|---|
Diversity of neuropsychiatric manifestations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Autoantibodies; Cytokines; Humans; Hydroxychloroqu | 2020 |
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antineoplastic Agents; Antirheumatic | 2018 |
5 other studies available for hydroxychloroquine and Nervous System Disorders
| Article | Year |
|---|---|
Broadening the spectrum of the neurological complications in systemic lupus erythematosus: A patient with meningoradiculitis.
Topics: Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Middl | 2022 |
Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Topics: Aged; Analgesics; Cardiovascular Diseases; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Diuret | 2021 |
Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.
Topics: Adult; Antimalarials; Brain; Chloroquine; Female; Humans; Hydroxychloroquine; Magnetic Resonance Ima | 1998 |
[Psychological and behavioral disorders with good outcome in neurosarcoidosis].
Topics: Adult; Antirheumatic Agents; Cognition Disorders; Drug Therapy, Combination; Facial Paralysis; Femal | 2001 |
Chloroquine neuromyotoxicity. Clinical and pathologic perspective.
Topics: Aged; Biopsy; Cardiomyopathies; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; | 1987 |